Human CD55/DAF Alexa Fluor™ Plus 680-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # AF2009AFP680
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Applications
Immunocytochemistry
Immunohistochemistry
Formulation, Preparation, and Storage
Formulation
Shipping
Stability & Storage
Background: CD55/DAF
CD55, also known as DAF or decay-accelerating factor, is a 70‑75 kDa member of the RCA family of proteins. Human RCA (regulators of complement/C’ activation) proteins are products of chromosome 1 genes that are ubiquitously expressed on cells exposed to plasma complement proteins (1‑4). A hallmark of RCA proteins is the presence of four to 30 SCRs (short consensus repeats; also called CCPs for C’ control protein modules) in their plasma-exposed regions. SCRs are characterized by a 60‑65 amino acid (aa) module that contains a highly conserved Trp residue and two internal disulfide bonds that create a beta-barrel structure (1). Human CD55 is synthesized as a 381 aa precursor that contains a 34 aa signal sequence, a 319 aa mature region and a 28 aa C-terminal prosegment (5, 6). The mature region contains four SCR modules and a C-terminal O-glycosylated extension (7). Following cleavage of the prosegment, a serine is exposed that serves as an anchor for a GPI-linkage (8). Multiple polymorphisms are found in the molecule. Alternate splicing also exists. One form that may not be translated shows an intron insertion in the prosegment, resulting in a 79 aa substitution for the standard C-terminal 20 aas of the prosegment (6). Another form generates a truncated 199 aa precursor that cannot be membrane-bound and may not be secreted (9). Mature CD55 is 53% and 84% aa identical to mouse and monkey CD55, respectively. CD55 is known to bind CD97 via the first SCR (4). It also binds physiologically-generated C3 convertases with its second and third SCRs (7, 10). Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells (1, 2). Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection (4).
References
- Herbert, A. et al. (2002) Biochem. Soc. Trans. 30:990.
- Miwa, T. and W-C. Song (2001) Int. Immunopharmacol. 1:445.
- Hourcade, D. et al. (2000) Immunopharmacology 49:103.
- Lea, S. (2002) Biochem. Soc. Trans. 30:1014.
- Medof, M.E. et al. (1987) Proc. Natl. Acad. Sci. USA 84:2007.
- Caras, I.W. et al. (1987) Nature 325:545.
- Lukacik, P. et al. (2004) Proc. Natl. Acad. Sci. USA 101:1279.
- Moran, P. et al. (1991) J. Biol. Chem. 266:1250.
- Lublin, D.M. et al. (1994) Blood 84:1276.
- Williams, P. et al. (2003) J. Biol. Chem. 278:10691.
Alternate Names
Gene Symbol
UniProt
Additional CD55/DAF Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only